China Adds 107 Drugs to 2026 Insurance Catalogue as CAR-T Cancer Therapy Gains First Entry

New coverage brings an expensive cancer treatment into basic insurance

China has added 107 medicines to its 2026 national basic medical insurance catalogue, including the first CAR-T cancer therapy to enter the scheme, in an update announced in Suzhou, Jiangsu province, on November 14, 2026. The revised catalogue takes effect on January 1, 2027, and covers 3,331 medicines.

The National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the update alongside a separate list for commercial health insurance. Of the 107 additions to basic insurance, 51 are Category 1 innovative drugs, a record number. The additions address treatment needs in cancer, rare diseases, chronic illnesses and mental health.

The most closely watched addition is relmacabtagene autoleucel injection, sold as Benoda by JW Therapeutics. Previously priced at 1.29 million yuan per dose, it becomes the first and currently only CAR-T medicine in the basic insurance catalogue. The treatment uses a patient's own immune cells, modified to attack cancer.

Negotiated insurance entry could bring its price to around 300,000 yuan or lower, with some industry estimates putting the patient's payment after reimbursement below 100,000 yuan. The final negotiated price, reimbursement conditions and resulting patient bill have not been publicly specified in the announcement details. Those figures therefore remain estimates.

For families considering a treatment that previously cost more than a million yuan, the change creates a new route to financial support. Access will also depend on whether patients meet treatment and insurance conditions and can receive care at a hospital equipped to deliver the therapy.

What changes in the national medicine list?

The 2026 catalogue contains 1,935 Western medicines and 1,396 Chinese patent medicines, meaning prepared traditional Chinese medicines. The update is the ninth consecutive annual adjustment since the National Healthcare Security Administration was established.

Authorities removed 34 medicines with limited clinical value, better alternatives, or missing prescribing information combined with an inability to supply them. The revision therefore changes the mix of treatments available through insurance as well as adding new options.

The catalogue records a net increase of 78 numbered entries after additions, removals and the consolidation of dosage forms. That numbering process matters when comparing annual totals: medicines supplied in different forms can be grouped or reorganised during an update.

Authorities also revised the names of traditional Chinese medicinal slices in line with the 2025 Chinese Pharmacopoeia, China's official standards for medicines. Some entries were combined, leaving 885 entries in that category. These medicinal materials are recorded separately from the headline total of 3,331 medicines.

Nearly half the additions are innovative drugs

The 51 Category 1 innovative drugs account for about 48% of the 107 additions. Category 1 is a Chinese regulatory classification for innovative medicines, and the number entering the catalogue this year sets a new record.

Cancer, rare diseases, chronic conditions and mental illness all feature among the treatment areas receiving new medicines. This gives the update a broader reach than the entry of CAR-T alone, extending it to patients who may need continuing treatment as well as those facing difficult cancers.

For a patient, insurance entry connects a medicine's availability with a way to help pay for it. Regulatory approval allows a product to be marketed for specified uses; inclusion in an insurance catalogue creates a route to reimbursement under the scheme's rules. Benoda's move into basic insurance brings those two stages together for a treatment whose price had placed it beyond many families.

How Benoda works and which patients it treats

CAR-T stands for chimeric antigen receptor T-cell therapy. T cells are part of the immune system. In this treatment, clinicians collect a patient's cells, modify them with genetic instructions so they can recognise a cancer target, grow them in a laboratory and return them to the patient.

Benoda has three approved indications in China, all involving adults with particular forms of lymphoma, a cancer affecting cells of the immune system. The approvals cover:

• Large B-cell lymphoma that has returned or resisted treatment after at least two previous lines of systemic therapy.
• Follicular lymphoma that resists treatment or returns within 24 months, after at least two previous lines of systemic therapy.
• Mantle cell lymphoma that has returned or resisted treatment after at least two previous lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.

A line of therapy means a course or stage of treatment. Systemic treatment works throughout the body, while a Bruton tyrosine kinase inhibitor blocks a protein involved in the growth and survival of certain cancer cells. These conditions place Benoda's approved uses among patients whose disease has already proved difficult to control.

CAR-T can produce powerful responses in some blood cancers, but its manufacture is more involved than making a conventional medicine in bulk. Each patient's cells must pass through collection, modification, production and quality checks before infusion.

How large could the price reduction be?

Benoda's previous price of 1.29 million yuan per dose sits near the upper end of the roughly 900,000 to 1.3 million yuan range cited for CAR-T products marketed in China. Patients previously often paid the full cost themselves or sought support through commercial health insurance.

Market information has put Benoda's possible insurance price at 300,000 yuan per dose, while other industry estimates place it below that level. Using 300,000 yuan as a comparison, the reduction from 1.29 million yuan would be 990,000 yuan, or about 77%.

The patient's share comes after the medicine's price is set. A lower negotiated price reduces the starting bill; reimbursement then determines how much of the eligible cost insurance pays. That is why a possible price near 300,000 yuan and an estimated patient payment below 100,000 yuan describe different stages of the same calculation.

Even at the lower estimated patient payment, the expense would remain substantial for many households. The practical value of the policy will depend on the combination of the negotiated price, insurance payment and access to a treatment centre.

Why manufacturing costs matter

JW Therapeutics chairman and chief executive Tian Feng has linked wider access to continued reductions in production costs. One key material is the lentiviral vector, a modified virus used to deliver the genetic instructions that help turn a patient's T cells into CAR-T cells.

The vector is among the most expensive raw materials in production. Tian said that this material had long depended heavily on imports and that the company had achieved a breakthrough through its own research and development.

Manufacturers also face limits on how far they can spread costs across large volumes. Benoda is made from the cells of the individual receiving it, so producing another patient's treatment requires another production process, with its own checks and handling.

China had approved 10 CAR-T medicines by early November 2026, increasing competition. Zhao Heng, founder of healthcare strategy consultancy Latitude Health, said Benoda's entry into basic insurance could push prices down across the sector. He also identified the development of cheaper next generation products as a direction for the industry, with progress depending on the timing of technical breakthroughs.

A separate catalogue expands commercial insurance options

The commercial health insurance innovative drug catalogue added 12 medicines and now contains 28. All 12 products that participated in this year's price discussions for that catalogue were included.

The additions include a treatment described as the world's first CAR-T therapy for solid tumours and China's first gene therapy for haemophilia. Solid tumours form masses in organs or tissues, unlike blood cancers such as lymphoma. Haemophilia is a condition in which blood does not clot properly, leading to prolonged bleeding.

The commercial catalogue also includes CAR-T products from Shanghai Hrain Biotechnology and Precision Biotech, identified in Chinese as 雷尼基奥仑赛注射液 and 普基奥仑赛注射液. The 2026 commercial list includes two CAR-T products.

Commercial coverage serves a different payment route from basic medical insurance. Medicines on the commercial list can be covered through commercial health insurance products, while the basic insurance fund does not pay for them through that listing. The list gives insurers a reference for designing benefits and selecting medicines to cover.

From commercial listing to basic insurance

Benoda entered the first commercial health insurance innovative drug catalogue in late December 2025. Its move into basic insurance less than a year later illustrates how a medicine can progress between the two payment systems.

National Healthcare Security Administration director Zhang Ke said two medicines from the commercial catalogue had entered basic insurance this year. He said the administration had established a mechanism connecting the two catalogues and that the medicines would retain relevant exemption support policies for clinical use.

Benoda's recent milestones show how catalogue decisions and hospital availability have developed:

• Late December 2025: Benoda entered the first commercial health insurance innovative drug catalogue.
• March 2026: Hunan Cancer Hospital made its first purchase of Benoda, becoming the first hospital in Hunan to procure a commercial CAR-T cell therapy product.
• November 14, 2026: Authorities announced Benoda's inclusion in the basic insurance catalogue at the innovative drug development conference in Suzhou.
• January 1, 2027: The revised national catalogue takes effect.

The Hunan purchase shows a concrete step between a national listing and treatment availability: a hospital obtaining the product. For a personalised cell therapy, access requires both a payment route and medical institutions able to organise its delivery.

Wider distribution, but access remains limited

Huang Xinyu, director of the National Healthcare Security Administration's department of medical services management, gave figures showing the reach of the first commercial catalogue. By the end of October 2026, its 18 medicines were stocked at 1,710 medical institutions and designated retail pharmacies.

Those medicines had been used in nearly 30,000 treatment instances, generating about 600 million yuan in sales. The number of institutions stocking them was about 140% higher than before their inclusion, while monthly sales had risen 70%. Treatment instances count uses and can include repeated treatment of the same person.

Tian estimated that fewer than 4% of patients meeting CAR-T indications receive the treatment each year. That leaves a large gap between the patients who might qualify and those who actually reach treatment.

Tian, speaking as JW Therapeutics' chairman and chief executive, described basic insurance entry as a major step while stressing that wider access would take time:

Inclusion in medical insurance is a key milestone in making CAR-T more widely accessible, but making it widely accessible is a gradual, long-term process.

JW Therapeutics plans to develop its distribution channels and medical education work, including training for clinicians with medical institutions and academic societies. Those plans address another part of access: doctors need to identify eligible patients and connect them with centres that can deliver treatment.

What changes when the catalogue takes effect?

January 1, 2027, is the next fixed date for patients, hospitals and insurers. From then, the revised catalogue becomes the basis for coverage of the newly listed medicines under the applicable payment rules.

Benoda's entry brings a treatment previously priced at 1.29 million yuan into the basic insurance system for the first time. Alongside it, 106 other additions extend the catalogue across several areas of urgent clinical need, while the commercial catalogue continues to provide another route for medicines outside basic coverage.

The central change is a broader set of ways to pay for innovative treatment. Whether that translates into more patients receiving care will depend on the bill they face and whether the medicine reaches the institutions treating them.

Key Points

• China announced its 2026 basic medical insurance catalogue in Suzhou on November 14, with implementation set for January 1, 2027.
• The update adds 107 medicines, including a record 51 Category 1 innovative drugs, and removes 34.
• The revised basic catalogue contains 3,331 medicines: 1,935 Western medicines and 1,396 Chinese patent medicines.
• JW Therapeutics' Benoda becomes the first and currently only CAR-T medicine included in basic insurance.
• Benoda previously cost 1.29 million yuan per dose; estimates of a price around 300,000 yuan or lower await confirmed payment details.
• The separate commercial health insurance innovative drug catalogue adds 12 medicines and now contains 28.